Nystatin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Nystatin: From Fungal Infections (Candidiasis) to Vulvovaginitis
One-Sentence Summary
Nystatin is a polyene antifungal originally used to treat Candida (yeast) infections of the skin and mucous membranes. The TxGNN model predicts it may be effective for Vulvovaginitis, with 0 registered clinical trials but 20 publications currently supporting this direction. Note: the evidence pack contains no SAHPRA-specific indication text or product information for Nystatin, as it is currently not marketed in South Africa.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (candidiasis) — based on established pharmacological knowledge; no SAHPRA-specific indication text is available (drug not marketed in South Africa) |
| Predicted New Indication | Vulvovaginitis |
| TxGNN Prediction Score | 99.92% (rank 729) |
| Evidence Level | L3 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (data gap DG002). Based on well-established pharmacological knowledge, Nystatin is a polyene antifungal that binds directly to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and fungal cell death. Its efficacy against Candida species in fungal infections has been proven for decades.
Vulvovaginitis — and vulvovaginal candidiasis specifically — is estimated to be the second most common cause of vaginitis after bacterial vaginosis, with Candida albicans accounting for 85–90% of cases (PMID 25775428, 19454049). Because the causative organism of most vulvovaginitis cases is the same fungal genus Nystatin was developed against, the mechanistic link here is direct rather than speculative: this is closer to a well-established off-label/legacy use than a novel biological hypothesis.
Historically, Nystatin was in fact a first-line topical treatment for vulvovaginal candidiasis before being largely superseded by imidazole and triazole antifungals due to convenience of dosing (PMID 1436934). Contemporary literature also positions Nystatin as a relevant alternative in fluconazole-resistant vulvovaginal candidiasis (PMID 39771534, 32104010), suggesting renewed clinical interest where azole resistance is a concern.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20406393 | 2011 | Cohort | Mycoses | In vitro fluconazole and nystatin susceptibility correlated with clinical outcome in 283 patients with complicated VVC (287 Candida isolates) |
| 32104010 | 2020 | In vitro study | Infection and Drug Resistance | Nystatin (and ZnO nanoparticles) downregulated SAP1-3 virulence gene expression in fluconazole-resistant C. albicans isolates from VVC |
| 30359236 | 2018 | Animal study | BMC Microbiology | Nystatin enhanced mucosal immune response and protected vaginal epithelial ultrastructure in a rat model of VVC |
| 16047929 | 2005 | Cohort | Ceska gynekologie | Vaginal combination therapy with nystatin and nifuratel evaluated for mixed/miscellaneous vulvovaginitis |
| 37023426 | 2023 | Comparative study | J Infect Dev Ctries | Compared tea tree oil (5%, 10%) and nystatin inhibition zones against vaginal Candida isolates in pregnancy |
| 1436934 | 1992 | Review | Obstet Gynecol Clin North Am | Reviews topical antifungals; notes nystatin was the original 1950s treatment for VVC, later surpassed by imidazoles/triazoles |
| 39771534 | 2024 | Review | Pharmaceutics | Update on fluconazole-resistant VVC management; nystatin discussed among alternative antifungal therapies |
| 21774671 | 2011 | Review | J Womens Health | Reviews boric acid for recurrent VVC, with nystatin as comparator context in azole-resistant disease |
| 4919155 | 1970 | Review | Med Clin North Am | General clinical review of nystatin pharmacology and use |
| 25775428 | 2015 | Review | BMJ Clinical Evidence | Epidemiology of vulvovaginal candidiasis; C. albicans causes 85-90% of cases |
South Africa Market Information
Nystatin currently has 0 SAHPRA registrations and is not marketed in South Africa. No product listings, registration numbers, or approved indication text are available in this evidence pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: This evidence pack flags a blocking data gap (DG001) — no regulatory warnings/contraindications data was available for review — meaning a formal safety assessment (S1 stage) has not yet been completed for this candidate.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link is strong and long-established — Candida species cause the majority of vulvovaginitis cases, and Nystatin’s antifungal action against Candida is well documented in 20 supporting publications, including data on efficacy against fluconazole-resistant strains. However, no clinical trials specifically test Nystatin in vulvovaginitis, and the drug is not currently registered in South Africa, so this remains guarded rather than a clear “Go.”
To proceed, the following is needed:
- Regulatory PI (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism of action detail from DrugBank (DG002)
- A SAHPRA registration/importation pathway assessment, since the product is not currently marketed in South Africa
- Ideally, a prospective clinical trial or comparative study against standard-of-care azole antifungals for vulvovaginitis in a South African population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.